«Between 2000 and 2011, only 4% of newly approved products were for neglected diseases that affect middle and low-income countries.» Pedrique, B. et al (2013) Lancet Global Health, 1(6):e371-379
«The current system for developing drugs incentivises high prices and delivers short-term returns to shareholders, rather than focusing on riskier, longer-term research which leads to critically needed therapeutic advances.» Mazzucato, M. et al (2018) The people’s prescription, UCL Institute for Innovation and Public Purpose Policy Report